Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy
- PMID: 19111874
- DOI: 10.1016/j.ccr.2008.12.011
Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy
Abstract
While targeting VEGF has shown success against a number of human cancers, drug resistance has resulted in compromised clinical benefits. In this issue of Cancer Cell, Crawford et al. (2009) report that tumors resistant to anti-VEGF therapy stimulate tumor-associated fibroblasts to express proangiogenic PDGF-C, implicating it as a potential therapeutic target.
Comment on
-
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment.Cancer Cell. 2009 Jan 6;15(1):21-34. doi: 10.1016/j.ccr.2008.12.004. Cancer Cell. 2009. PMID: 19111878
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
